EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study

Yen-Fu Chen, Hsin-Han Hou, Ning Chien, Kai-Zen Lu, Ying-Yin Chen, Zheng-Ci Hung, Jung-Yien Chien, Hao-Chien Wang, Chong-Jen Yu

Lung · 2024

DOI: 10.1007/s00408-024-00707-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Lung, 2024. Verfasst von Yen-Fu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Yunlin Branch, Yunlin County, Taiwan. Hauptthemen laut MEDLINE: Bronchiectasis, Biomarkers, Immunoglobulin E, Eosinophils. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Taiwan University Hospital, Yun-Lin Branch, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Bronchiectasis is predominantly marked by neutrophilic inflammation. The relevance of type 2 biomarkers in disease severity and exacerbation risk is poorly understood. This study explores the clinical significance of these biomarkers in bronchiectasis patients.

Methods

In a cross-sectional cohort study, bronchiectasis patients, excluding those with asthma or allergic bronchopulmonary aspergillosis, underwent clinical and radiological evaluations. Bronchoalveolar lavage samples were analyzed for cytokines and microbiology. Blood eosinophil count (BEC), serum total immunoglobulin E (IgE), and fractional exhaled nitric oxide (FeNO) were measured during stable disease states. Positive type 2 biomarkers were defined by established thresholds for BEC, total IgE, and FeNO.

Results

Among 130 patients, 15.3% demonstrated BEC ≥ 300 cells/μL, 26.1% showed elevated FeNO ≥ 25 ppb, and 36.9% had high serum total IgE ≥ 75 kU/L. Approximately 60% had at least one positive type 2 biomarker. The impact on clinical characteristics and disease severity was variable, highlighting BEC and FeNO as reflective of different facets of disease severity and exacerbation risk. The combination of low BEC with high FeNO appeared to indicate a lower risk of exacerbation. However, Pseudomonas aeruginosa colonization and a high neutrophil-to-lymphocyte ratio (NLR ≥ 3.0) were identified as more significant predictors of exacerbation frequency, independent of type 2 biomarker presence.

Conclusions

Our study underscores the distinct roles of type 2 biomarkers, highlighting BEC and FeNO, in bronchiectasis for assessing disease severity and predicting exacerbation risk. It advocates for a multi-biomarker strategy, incorporating these with microbiological and clinical assessments, for comprehensive patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisBiomarkersImmunoglobulin EEosinophilsNitric OxideHumansFemaleMaleMiddle AgedProspective StudiesCross-Sectional StudiesAgedLeukocyte CountSeverity of Illness IndexBronchoalveolar Lavage FluidNeutrophilsPseudomonas aeruginosaBreath TestsDisease ProgressionPseudomonas InfectionsAdult

Stichwörter der Autor:innen

Pseudomonas aeruginosaBlood eosinophil countBronchiectasisFractional exhaled nitric oxideImmunoglobulin EType 2 biomarkers

Substanzen

BiomarkersImmunoglobulin ENitric Oxide

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital, Yunlin Branch, Yunlin County, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Thoracic Medicine Center, Department of Medicine and Surgery, National Taiwan University Hospital, Yunlin Branch, Yunlin County, Taiwan.
  • Graduate Institute of Oral Biology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Medical Imaging, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Taiwan University Hospital, Yun-Lin Branch, Taiwan

Zitieren

APA

Chen, Y. F., Hou, H. H., Chien, N., Lu, K. Z., Chen, Y. Y., Hung, Z. C., Chien, J. Y., Wang, H. C., & Yu, C. J. (2024). Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study. Lung. https://doi.org/10.1007/s00408-024-00707-0

Vancouver

Chen YF, Hou HH, Chien N, Lu KZ, Chen YY, Hung ZC, et al. Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study. Lung. 2024. doi:10.1007/s00408-024-00707-0

BibTeX
@article{Chen2024,
  author = {Chen, Yen-Fu and Hou, Hsin-Han and Chien, Ning and Lu, Kai-Zen and Chen, Ying-Yin and Hung, Zheng-Ci and Chien, Jung-Yien and Wang, Hao-Chien and Yu, Chong-Jen},
  title = {Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study},
  journal = {Lung},
  year = {2024},
  doi = {10.1007/s00408-024-00707-0}
}
Kostenlos starten →